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Executive Summary
Emergency contraception (EC) affords the opportunity of avoiding an unintended pregnancy after
unprotected sexual intercourse. In its most common form, oral contraceptive pills, EC provides
protection for up to 120 hours after intercourse. Alternatively, an intra-uterine contraceptive device
(IUCD) can be inserted, no later than five or six days after intercourse. IUCDs have proven effective and,
by expanding contraceptive choices, have transformed the sexual and reproductive lives of millions of
women around the world. Despite significant progress in product development, procurement, and
distribution in the past few decades, EC’s capacity to benefit many women, in countries such as Nigeria,
is hampered by several issues, including EC knowledge, attitudes, and practices among providers and
opinion leaders, all of which are perceived as potential barriers to EC, but are not well understood.
To better understand these issues, The Population Council, with support from the International
Consortium for Emergency Contraception, documented EC-related knowledge, attitudes, and practices
among EC providers in Nigeria. Recognizing that providers do not operate in a vacuum, this study also
assessed perceptions of key opinion leaders (KOLs) who help shape the policy environment for EC and
family planning (FP) in general. The study is a part of a multi-country project also including India and
Senegal.
Findings suggest significant gaps in provider EC knowledge, attitudes, and practices in Nigeria,
potentially necessitating continuous training and re-training to help dispel misperceptions and negative
attitudes. For example, many providers will not distribute EC to young, unmarried women, and clear
instructions or counseling are rarely included when EC is provided. Moreover, almost all sampled
providers were not aware that dedicated EC pills can provide protection for as many as five days postintercourse, despite its categorical statement in the country’s FP service protocols.
Sampled KOLs demonstrated enthusiasm for supporting the method, but the Nigerian Government and
its officials must support endorsement with action. While key policy stakeholders’ attitudes towards EC
are favorable, its procurement, distribution, and monitoring systems and procedures are currently almost
entirely managed by non-governmental organizations (NGOs) and the private sector. In Nigeria, where
much of the health infrastructure, facilities, and human resources are controlled by government, the
public sector must play a greater role in providing EC-supportive policies and practices, and in
monitoring their implementation.
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vii

Introduction
Studies have shown a high proportion of all pregnancies in sub-Saharan Africa are unintended (Cleland et
al. 2011). As a result, many end in termination through induced abortion. In countries such as Nigeria,
where abortion law is highly restrictive, termination is commonly performed by unqualified persons, or in
places not meeting required sanitary and technical standards, thereby propagating unsafe abortion, an
important contributor to unacceptably high maternal mortality and morbidity ratios in many developing
countries (Population Council and PSI 2009). Unsafe abortion remains a serious challenge to Nigeria’s
health system, a country with a maternal mortality ratio (MMR) estimated at 545 maternal deaths per
100,000 live births (NPC 2009). Unsafe abortion, as a result of unintended pregnancies, is identified as
one of the leading causes of maternal deaths in Nigeria (Ebuehi et al. 2006).
With stringent legal and social restrictions to safe abortion in Nigeria, EC could play an important role in
preventing unintended pregnancies, among both married and unmarried women who have had
unprotected intercourse. EC is safe and effective in preventing unintended pregnancy, by either inhibiting
or delaying, before ovulation, ovarian egg release, or potentially preventing sperm and egg convergence,
by affecting cervical mucus or spermal binding ability. Although Nigeria’s Federal Ministry of Health
National Family Planning Guidelines lists EC among other modern contraceptive methods as a nonprescription drug sold over the counter, EC use remains very low in Nigeria (FMoH 2010, NPC 2009).
Few studies in recent years, however, have investigated provider EC knowledge, attitudes, and practices
in Nigeria, and to the best of our knowledge, no study has investigated KOLs’ EC perceptions and
attitudes. The knowledge, attitudes and practices of EC providers, who are key gatekeepers, must be
investigated, with gaps therein addressed. Perceptions of policy makers who both shape the general FP
commodity environment, including EC, and enforce regulations affecting provider practices, need to be
assessed. These issues constitute the study’s main focus.

Review of the literature
Providers’ EC knowledge

A 1998 study by the Society for Family Health (SFH) demonstrated a paucity of EC knowledge among
health care providers in Nigeria. Only 61 percent of interviewed providers across the country knew of an
EC method; Postinor was the only pill specifically packaged for EC (Society of Family Health 1998). EC
knowledge varied regionally: It was higher in the southern zone than in the north (SFH 1998). In the
southwest region, where EC knowledge seems high, only 33 percent of providers knew any effective
method, with wide rural-urban differences (22.4% and 5.8% respectively). Local pharmacy personnel
were most aware of effective contraception methods, while those at patent medical stores showed
poorest understanding of effective EC methods (SFH 1998).
The SFH study also reported that 29 percent of providers expressed belief that EC could result in
infertility. Prescription method inconsistency also prevailed, reflecting a lack of detailed knowledge. No
providers interviewed knew Postinor’s dosage, side effects, and mechanisms of action, and only five
providers (of 443) correctly stated the timing, as an EC agent, of IUCD insertion (SFH 1998).
The knowledge and attitudes of other trained health professionals, such as doctors, nurses, pharmacists,
and hospital administrators, have been studied by Adekunle et al. (2000) in Ibadan, and their findings
were not significantly different. For example, only 35 percent of respondents were aware that combined
estrogen/progestin or progestin-only pills can be used as EC, and only 27 percent were aware IUCDs
could be used as EC. Similarly, Obionu (1998) found, in Enugu, southeast Nigeria, that only 39 percent
1

of health professionals were aware of an EC pill, and fewer still (26%) were aware of IUCDs’ potential
contraceptive use. More worryingly, 29 percent of the sample who knew of an EC product expressed the
belief its use was associated with infertility.
Although recent studies suggest improvement in EC provider knowledge in Nigeria, the situation is still
far from ideal. As recently as 2006, 90 percent of health providers in Lagos State knew of an EC method,
and 75 percent knew it could prevent pregnancy, but only 50 percent knew correct timing of
administration, and only 10 percent were able to recognize the drug, its side effects, and dosage (Deborah
2007, Ebuehi et al. 2006). Most alarmingly, only two thirds of providers who knew of an EC method
were aware it is legal in Nigeria. Okonofua et al. (2009) reported, from a survey of private medical
practitioners (mainly doctors) in four Nigerian geo-political zones, that, while 80 percent of respondents
correctly described EC methods, only 14 percent reported correct brands and dosages of ECs currently
available in the country, and fewer still knew the exact timing for EC use.
Fayemi et al. (2010) report that the preferred service delivery point for EC in Nigeria, especially among
young women, is patent medicine vendors, but only 46 percent of these vendors could correctly describe
an EC, in terms of pregnancy prevention use. Less than 10 percent of patent vendors said it is a drug
used after sex, and only three percent could mention a brand name (Postinor).
In another study, about 80 percent of senior health professionals in Borno State (Northeast Nigeria)
reported hearing of EC, with awareness lower among nurses (70%). Even so, up to 10 percent of these
respondents were not sure of the correct timing of administration (Geidam, Kullima and Saddiq 2009).
Table 1 summarizes selected findings from previous research on EC knowledge among providers.
Table 1: EC understanding among providers in Nigeria, based on selected variables
Authors and location of research

Variable of interest

Measure

SFH, across Nigeria (1998)

Knowledge of existence of EC

60%

Obionu, Enugu (1998)

Belief that EC causes infertility

29%

Obionu, Enugu (1998)

Knowledge of IUCDs as EC

26%

SFH, across Nigeria (1998)

Knowledge of side-effects/dosage and mechanism of
action of Postinor

0%

Adekunle et al., Ibadan (2000)

Knowledge of IUCDs as EC

27%

Adekunle et al., Ibadan (2000)

Knowledge of progestin/oestrogen or progestin-only pills
as EC

35%

Deborah, Lagos (2007) & Ebuehi
et al., Lagos (2006)

Recognition of EC pills and knowledge of side effects
and dosages

10%

Deborah, Lagos (2007) & Ebuehi
et al., Lagos (2006)

Knowledge of legality of EC in Nigeria

66%

Geidam, Kullima & Saddiq, Borno
(2009)

Not sure of correct timing of EC

10%

Okonofua et al., across Nigeria
(2009)

Knowledge of available brands and correct dosages

14%
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It is clear there is a paucity of knowledge and awareness of EC among all cadres of health care providers
in Nigeria. This fact may, partly, explain why EC use among potential users is lacking, with widespread
confusion about the exact mode of EC’s operation particularly notable.
Providers’ attitudes towards EC

Previous studies of EC providers also report findings on attitudes. Society for Family Health (1998), for
example, found about 80 percent of all providers in Nigeria approved of EC, across all regional, religious,
ethnic, and gender categories. Among the minority of providers disapproving of EC, reasons included
religious belief, adverse side effects, EC as abortificient, and its use encouraging immorality, especially by
unmarried adolescents (Deborah 2007, Ebuehi et al. 2006, Adekunle et al. 2000). It is not surprising,
therefore, the majority of doctors, nurses, and pharmacists interviewed in Ibadan identified sexual assault
(64%) as the only appropriate indication for EC (Adekunle et al. 2000). Table 2 describes documented
common negative attitudes towards EC in Nigeria.
Table 2: Negative attitudes of EC providers in Nigeria
Prevailing attitudes

Source

Forbidden by religion

SFH Nigeria (1998)

EC an arbotificient

SFH Nigeria (1998), Deborah (2007) and Ebuehi et al. (2006)

EC encourages immorality

SFH Nigeria (1998)

EC causes infertility

Adekunle et al. 2000

EC providers’ practices

Of the 735 highly trained medical professionals—physicians and pharmacists—surveyed by Adekunle et
al. in 2000, only 16 percent had ever prescribed the combined pills as EC, only 11 percent had ever
prescribed the progestin-only pill, and only eight percent had prescribed an IUCD for EC. While 23
percent of private providers (predominantly doctors) across Nigeria offer EC services in their clinics,
only 36 percent of health care providers working in public sectors in Borno State ever prescribed EC
(Okonofua et al. 2009, Geidam, Kullima and Sadiq 2009).
Fayemi et al. (2010) also found, of patent medicine vendors (PMVs) who had ever dispensed EC in
Ibadan, over 79 percent were actively dispensing. For PMVs not dispensing EC, reasons included fear of
harassment by State Ministry of Health (SMoH) and police, religious beliefs, and fear of sanction from
the National Drug Law Enforcement Agency (NDLEA) and National Agency for Food and Drug
Administration and Control (NAFDAC); others include fear of side effects, low demand, or product
stock-out.
The current study provides opportunity for better understanding EC provider attitudes in Nigeria in a
range of issues, but particularly the question of repeated use, and describing changes that have potentially
occurred in the intervening period.
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Context and Rationale
Nigeria is the most populous country in Africa, with a 2010 estimated population of 160 million (Federal
Government of Nigeria 2011). With a growth rate of 2.8 percent, the country is expected to double its
population in 25 years if the current total fertility rate (5.7) and other determinants remain the same
(Population Reference Bureau 2010). Nigeria’s maternal and infant mortality are among the highest in the
world: 545 per 100,000 and 75 per 1000, respectively (NPC 2009). Contraceptive prevalence for modern
FP methods is 10 percent, and much lower for EC (less than 1%).
Within this demographic context, assessing FP providers’ knowledge, attitudes, and practices, especially
regarding EC, will improve understanding of and strengthening for the supporting environment for EC’s
supply and use. In addition, the perceptions of KOLs and policy makers, regulators of these
environments, and important influencers of health-seeking behaviors, will be assessed. Once these issues
become clearer, more definite programmatic recommendations could be made.
Two urban centers were purposively selected—Abuja and Kaduna, in central and northwest Nigeria,
respectively. Abuja, the Federal Capital Territory, is home to all ethnic populations, with a total
population of approximately 1.4 million. As the seat of federal government, Abuja attracts the young and
energetic migrating there in search of employment and other opportunities. Regrettably, the majority of
this population lives in sprawling slums, exposing them to poor and substandard housing, without clean
water and basic sanitation, and with insecurity and poor health services.
Kaduna is traditionally the political center of northern Nigeria and, therefore, harbors a large number of
migrants mostly residing in unplanned, poorly serviced settlements. The most recent census placed
Kaduna’s total population at nearly 800,000 (National Population Commission 2009a). Kaduna, as with
the rest of the region, has health and development indices worse than national averages; for example,
contraceptive prevalence for the Northwest region is 4.6 percent (NPC 2009b).

Methodology
This study is a cross-sectional survey of providers’ and stakeholders’ beliefs, attitudes, and practices
concerning EC provision and use in Kaduna and Abuja. A semi-structured questionnaire was developed,
pilot-tested, and utilized for interviewing both public and private sector providers. Various stakeholders
and KOLs directly or indirectly involved in providing, or influencing, continued EC availability and use
were also interviewed using an in-depth interview (IDI) guide.
Provider survey

A simple, random sample of providers drew from a sampling frame (from health authorities in each city)
consisting of a list of PMVs, private and public FP clinics, and registered pharmacists in Kaduna and
Abuja. From every clinic or hospital (private or public) selected, the FP service head was interviewed, and
from every selected pharmacy and patent medical store the proprietor was interviewed. From these
sampling frames, 735 providers were selected. A pre-survey questionnaire indentified 550 providers in the
two cities currently providing, or who have ever provided, EC. The minimum sample size was 364 and,
allowing for non-response of 10 percent, a total of 407 providers were interviewed. To eliminate data
entry errors and reduce time for data entry, a scan-able questionnaire for data collection was used, with
data entered centrally. Data were cleaned, and files were created in EPI-INFO and SPSS. A codebook
and frequency distribution of the variables and a plan of analysis and outline report with dummy tables
were developed prior to data analysis and report writing.
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Key Opinion Leaders’ interviews

In Abuja, key stakeholders were purposively selected from members of the national legislative houses (i.e.
chairs of the Senate and House of Representatives health committees); officials of the federal ministries
of Health and Women’s Affairs; heads of relevant professional associations such as the Nigeria Medical
Association, Pharmacists’ Council of Nigeria, and National Association of Nurses and Midwives; relevant
pharmaceutical companies and leading social marketing organizations; religious leaders; and leaders of
reproductive health (RH) and women’s rights-focused civil society organizations (CSOs). Thirteen of
these key stakeholders were interviewed by Council staff, and their responses were recorded with tape
recorders and written notes, transcribed verbatim, with content analysis based on four pre-determined
domains (see below).
Ethical considerations

IRB approval was obtained from both the Nigerian Institute for Medical Research (NIMR) and the
Health Research Committee of the Federal Capital Development Authority (FCDA). Each participant
was informed of the research’s nature and was also informed that everything they said would remain
confidential, their names would not be recorded, no payment would be made for participation, they had
the right to not answer any question, and that they could terminate the interview at any point if they felt
uncomfortable. Signed consent was obtained from every participant.

Study Findings
Providers’ characteristics

The average age of the 407 providers was 35, with 56 percent male and 44 percent female, a reflection of
the labor force’s overall gender imbalance. Most providers interviewed were pharmacists (36%), followed
by PMVs (30%), private sector hospital and clinic staff (22%), and public sector hospital and clinic staff
(12%). The high proportion of pharmacists as EC providers indicates their gradual increase in EC
dispensation, which may be a desirable development, since pharmacists are better qualified and more
informed than PMVs about EC and modern contraception in general (SFH 1998).
Providers’ EC knowledge, attitudes, and practices

In the 1990s, Postinor 2 was the only dedicated EC commodity available in Nigeria. This study revealed a
broadening of the range of EC brands, indicated in Figure 1.
Figure 1: EC products provided by SDPs and facilities in 2011
100.0%
80.0%

89.9%
75.3%

60.0%
40.0%
20.0%

8.5% 10.1%

11.8%14.1%

LNG

OC pill pack

4.2% 5.0%

0.0%
Potinor2

By responses

By SDP/Facilities
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Others

Of 407 providers interviewed, 125 (31%) have been trained in FP counseling, and this is much higher for
EC specifically (57%). Some providers had obtained brochures or other forms of information around EC
from the marketing representatives (39%). The Federal Ministry of Health and women’s health NGOs
were not major sources of information for providers on EC (16% and 3% respectively).
Three-quarters of providers could correctly describe how EC works, which displays remarkable progress
since the 1990s, when no interviewed providers were aware of how Postinor 2 works (SFH 1998). Ten
percent of providers still consider EC an abortifacient, but which is an improvement compared with
earlier studies, which found up to 32 percent of providers in Lagos thought EC is an abortifacient
(Deborah 2007, Ebuehi et al. 2006). Only 29 percent of providers knew, however, that all women are
eligible for EC. Remarkably, only one provider (0.2%) was aware EC pills are protective for up to 120
hours after unprotected intercourse, despite current Nigerian EC service delivery guidelines clearly
affirming this (Revised National Family Planning Service Protocols 2010).
Overall, only 12 percent of providers could be categorized as exhibiting comprehensive EC knowledge,
knowing at least four of the five questions on EC knowledge. Factors significantly associated with
comprehensive knowledge of how EC works included:
•
•
•
•

Ever received FP counseling training, AOR 1.9 (CI1.02, 3.67)
Ever received training on EC specifically, one year prior to survey AOR 1.54(CI 0.57, 4.18)
Ever received a brochure/information document, AOR 1.67(CI 0.50, 5.23)
Ever read an EC brochure/information document, AOR 1.91(CI 0.57, 6.69).

These patterns were also largely observed with other knowledge variables, as shown in Table 3.

Table 3: Factors associated with providers’ attitudes and beliefs about EC safety

Factors

Total
N

EC is safe to use
N (%)

p-value

AOR (95% CI)

114
251
42

106 (93.0)
237 (94.4)
38 (90.5)

0.594

1.00
1.25 (0.48, 3.24)
0.70 (0.19, 2.64)

228
179

213 (93.4)
168 (93.9)

0.859

1.00
1.14 (0.49, 2.63)

282
125

266 (94.3)
115 (92.0)

0.376

1.12 (0.44, 2.84)
1.00

177
230

170 (96.0)
211(91.7)

0.078

1.95 (0.73, 5.23)
1.00

165
242

156 (94.5)
225 (93.0)

0.525

4.63(0.23, 93.30)
1.00

149
258

140 (94.0)
241 (93.4)

0.827

0.21 (0.01, 4.23)
1.00

51
146
122
88

49 (96.1)
136 (93.2)
114 (93.4)
82 (93.2)

0.896

1.57(0.29, 8.42)
1.10 (0.38, 3.20)
1.24 (0.39, 3.93)
1.00

Age
<30
≥30
Unknown
Gender
Male
Female
Ever received FP counseling training
Yes
No
Ever received training on EC Specialty
Yes
No
Received any brochure/information document
Yes
No
Read the brochure/information document
Yes
No
SDP/Facilities
Public sector
Pharmacy
PMV
Private sector

6

Location
Kaduna
FCT
SDP possessed guidelines on EC provision
Yes
No

204
203

191(93.6)
190 (93.6)

0.990

1.00
1.0 1(0.44, 2.33)

268
139

254(94.8)
127(91.4)

0.182

1.44 (0.62, 3.34)
1.00

† Significant p<0.05

Table 4 illustrates Nigerian providers’ negative attitudes about EC.
Table 4: Providers’ attitudes and beliefs about EC use

Category
Safety
Efficacy
Access
Frequency
of EC use
Characteristics
of EC users

Opinions
EC is safe to use
EC is very effective for pregnancy prevention
Women should be provided with EC in advance of unprotected sex
EC should be available OTC without prescription
There is no maximum number of times a woman should use EC in a year
In one menstrual cycle, use EC each time after unprotected sex or each time it is needed
There should be guidance/advice on frequency of EC provision for women
Women who use EC repeatedly are not different from those who use once
They are not more likely to participate in risky sexual behaviors
They are not more likely to have more sexual partners
They are not more likely to have STIs
They are more likely to use other contraceptive methods
In the case of rape or sexual coercion
Infrequent or unpredictable sex
Not because of engaging in sex work
Unprotected sex and wishing to use EC
Married women
In refugee or conflict settings
Unmarried adolescent/young women
There should be no age restriction on EC use

N

%
93.6
65.8
66.8
33.2
23.1
17.7
89.9
35.4
30.0
35.6
22.1
57.2
49.6
20.4
100.0
40.0
55.5
11.8
14.0
14.0
407

Although 94 percent of providers expressed the belief that EC is safe, some negative attitudes were
observed as widespread among EC providers. Over 34 percent of providers did not believe EC is very
effective in preventing pregnancy, and two-thirds did not favor EC’s general availability, over the counter
(OTC) without a prescription. By implication, the subject of repeated use was not accepted by providers,
as only 23 percent and 18 percent agreed to no limit on EC use and EC provision whenever needed,
respectively. Fifty-seven percent of providers, however, had repeatedly provided EC to a client.
Ever received EC training and being a provider at a public facility are positively associated with
perceiving EC as safe; AORs 1.95 (95% CI 0.73, 5.23) and 1.57(95% CI 0.29, 8.42) respectively. Likewise,
ever having read a brochure/information document on EC is significantly associated with believing EC is
effective in preventing pregnancies; AOR 3.66 (95% CI 1.33, 10.08). Working at patent medical stores is
strongly and positively indicative of positive attitudes toward providing EC to any woman who had
unprotected intercourse. Table 5 (on page 13) indicates that belief in EC’s efficacy for pregnancy
prevention is strongly associated with prior exposure to specific information about EC.
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Table 5: Factors associated with providers’ attitudes/beliefs about EC’s efficacy for pregnancy prevention
Total
N

EC is very effective
for pregnancy prevention
N (%)

p-value

AOR (95% CI)

<30

114

75(65.8)

0.896

1.00

≥30

251

164(65.3)

1.35 (0.81, 2.26)

Unknown

42

29(69.0)

1.68 (0.75, 3.78)

Male

228

161(70.6)

Female

179

107(59.8)

Yes

282

178(63.1)

No

125

90(72.0)

Yes

177

119(67.2)

No

230

149(64.8)

165

105(63.6)

Factors
Age

Gender
0.022

1.00
0.64 (0.41, 1.00)

Ever received FP counseling training
0.081

0.61 (0.35, 1.05)
1.00

Ever received training on EC Specialty
0.606

1.42 (0.87, 2.31)
1.00

Received any brochure/information
document
Yes

0.437

0.28 (0.10,
0.75)†

No

242

163(67.4)

149

99(66.4)

1.00

Read the brochure/information
document
Yes

0.847

3.66 (1.33,
10.08)†

258

169(65.5)

Public sector

51

24(47.1)

Pharmacy

146

105(71.9)

No

1.00

SDP/Facilities
0.001

0.70 (0.34, 1.45)
1.99 (1.12,
3.56)†

PMV

89(73.0)

122

2.20 (1.17,
4.14)†

88

50(56.8)

Kaduna

204

122(59.8)

FCT

203

146(71.9)

268

185(69.0)

Private sector

1.00

Location
0.010

1.00
1.53 (0.98, 2.38)

SDP possessed guideline on EC provision
Yes

0.060

1.64 (1.02,
2.63)†

No

83(59.7)

139

† Significant p<0.05
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1.00

Table 6 describes the profile of EC users as reported by the providers. Most clients are predominantly
students or unmarried (60%) and married women (54%); one quarter of providers indicated usually
serving teenage adolescents (19 years or less).
Table 6: Profile of EC providers’ clients

Dominant age profile

N (%)

Mostly teenage/adolescent clients (≤19 years old)

104 (25.6)

Mostly student/unmarried clients

245 (60.2)

Mostly married women clients

220 (54.1)

Mostly men seeking EC for partners

34 (8.4)

The quality of information and services offered to clients by the providers was poor. Only 20 percent and
14 percent of providers reported offering information on side effects and responding to queries and
concerns respectively. In addition, 49 percent of the providers provide EC without giving instructions to
their clients (Table 7).
Table 7: Information and services to clients from EC providers
N (%)
Provision of EC Pills

105 (25.8)

Provision of general information about EC

199 (48.9)

Provision of instructions on how to use EC

208 (51.1)

Provision of information on side-effects

82 (20.1)

Respond to queries and concerns

58 (14.3)

Refer to family planning services

55 (13.5)

Key Opinion Leaders’ insights

Stakeholders’ support will, to a large extent, determine supply and demand, legality and regulation,
awareness of and support for, and public facility distribution, or lack thereof, of EC (Williams 2011). In
some countries, EC availability and accessibility have stalled due to groups opposed to FP generally and
those who perceive EC as abortifacient. EC’s global availability and affordability, however, have
increased over the last few years due multiple stakeholders’ efforts (Schiappacasse and Diaz 2006). In
some African countries such as Kenya, changing of policy support has affected commodity availability
and stability. As contraception policy expands and contracts, contraceptive availability and accessibility
also fluctuate, with RH repercussions in general (Crichton 2008).
KOLs’ role in matters of public health importance cannot, therefore, be overstated. In Nigeria, such
stakeholders’ perceptions of EC have not been carefully investigated. This study addresses the
perceptions of these Nigerian policy stakeholders in four areas: EC product knowledge; EC policy issues;
supply and demand; and their recommendations for improving EC supply and utilization.
KOLs’ awareness of EC products in Nigeria

In general, stakeholder knowledge of EC is encouraging. Government stakeholders, however, are
apparently not directly involved in EC regulation and have not played a role in EC in the past:
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Their awareness of EC is mostly based on speculations and assumptions, with a few exceptions. For
example, a federal legislator who reported never been involved or even informed of EC appears to have
little understanding of what EC is, or indeed FP generally:
“Well, when you talk of EC, what I believe is that a contraception that is given to a woman, most of
them are surgical contraception, in which a woman that is aborting, either induced or spontaneous, and
she needs to be assisted.” —Federal legislator
Even among those seemingly conversant with EC and its legality in the country, their responses were
more conjectural than factual, indicating remoteness from FP policy generally, and of EC particularly.
When asked about EC status and product knowledge in Nigeria, the following responses emerged:
“That is what I said. I don’t have any information about [EC’S legal status].”
—Departmental deputy director, FMoH
“As I am telling you … Because we are not managing it [EC] in the public sector supply, I don’t have
detailed information [of available EC products], but I know the social marketing—SFH does that. So
I don’t know the brand, whether it is Postinor 2 or 1.”
—Departmental deputy director, FMoH
In contrast to public sector stakeholders, those working with NGOs and donor agencies seemingly
understand the issue far better, which may reflect these different entities’ roles in FP provision in general:
“Well … legal status? Am not sure what you meant by that, but from my own understanding, do you
mean if the drug is approved to be used in Nigeria? If that is what you mean … the answer is Yes!
And in fact, the two products being distributed by Society for Family Health actually are registered by
NAFDAC, which is the highest drug approval body in Nigeria, that is … Postinor 2 and Pregnor
OCPs emergency contraceptives.”
—Deputy director, leading health social marketing organization
“Of course … from the Society for Family Health’s experience … we are battling with so much faking,
particularly of the leading product … Postinor 2 in Nigeria. In fact, you will see, if you go into the
market, what they call Postinor 10, which you and I know is fake, because Gedeon Richter … the
manufacturer … stopped producing Postinor 10 almost, like, 10 years ago. But if you still go into the
Nigerian market you will still see it. Where are they getting it from? Nobody knows. I sincerely believe
that what they are producing and distributing works for the clientele … if you go to the market, you will
still see various designs and shapes trying to imitate or copy what we are distributing. Of course, they are
fakes and not duly registered by NAFDAC.”
—Deputy director, leading health social marketing organization
“The legal status of emergency contraception in Nigeria … as far as contraceptive methods are concerned,
to the extent that they regulate fertility, it is very legal. There are a lot of policy statements from the
government … also protocols for the provision of such services, which are approved by the government …
So, to that extent, it is listed among contraceptives available for use in Nigeria. To that extent, that it is
listed as one of the various means to regulate fertility, it is legal … I cannot exactly pinpoint a particular
law that says it is legal. But the point am making is … to the extent that it is not prohibited by the
agencies that approve use of drugs in Nigeria … to that extent, it is legal.”
—Senior executive, national FP organization
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These examples illustrate the discrepancies in understanding among the two sectors. This is also observed
in areas such as EC product effectiveness and safety. Again, most public sector stakeholder responses
were conjectural as opposed to the firm knowledge and understanding demonstrated by stakeholders
from NGOs and donor organizations. Only one participant, from SFH, however, was aware of
counterfeit EC products in the Nigerian market. Most stakeholders, while acknowledging the possible
existence of counterfeit EC, were largely based on assumptions:
“What I mean is that in any system you cannot expect 100 percent success or 100 percent pure
provision of what is expected … definitely you will have some form of fake, and form of quackery and
another form of contraband products which usually infiltrate into the system. So even if I don’t believe,
am sure it exists … Yes!”—Senior executive, health sector regulatory agency
“As at the time I knew it in the ‘90s, there were no fakes, but now, I believe there are fakes for a
product with a big market and consumption” —Departmental head, regulatory agency
“Not to my knowledge [—of EC counterfeit].”
—Head of medical team, Muslim women’s NGO
Of the 13 stakeholders interviewed, less than half could describe how EC works. It is, however,
instructive and encouraging that no respondents described EC as abortifacient, a potential predictor for a
favorable EC policy environment in Nigeria, as the abortifacient belief may stall widespread EC adoption
in many countries (Fayemi et al. 2010).
EC was generally perceived as appropriate for people who need it, and all stakeholders interviewed
agreed there is dire EC need because of Nigeria’s social, health, and economic circumstances. Concerns
related to the possibility that widespread EC use could lead to lower barrier method use, with resultant
escalation in sexually transmissible infections (STIs). Stakeholders’ approvals of EC and concerns of
likely STI transmission escalation include:
“I think it is a good product … particularly where people have unpredictable sex. In Nigeria, a lot of
us have predictable sex and are in stable relationships, but it is excellent for young people whom, I
hope, will use EC in addition to condoms.” —Head of medical team, Muslim women’s NGO
“Well, the ones registered by NAFDAC are safe products! [giggles] So, I don’t want to speak on
generalization of the whole something … the ones registered by NAFDAC are safe and efficacious
and fit for use by the members of the public, and I do recommend them to the members of the public …
It should be in the health facilities, it should be in the pharmacies, patent medicine shops.”
—Deputy director, public relations unit, health sector regulatory agency
“Yes, it should be encouraged; people should have varieties for them to be able to make an informed
choice. That is it … It should be available.” —Deputy director, FMoH
Only a few stakeholders were aware of any previous EC research in Nigeria. Almost all, however, were
highly supportive of further EC research in Nigeria, believing that deeper understanding of how both EC
clients and providers perceive EC will better inform programming for increasing its availability,
accessibility, and use in Nigeria. Only one stakeholder, while acknowledging EC’s importance, did not
consider it worthy of further research.
“Well, I am not aware of any research on emergency contraception … So, it goes to say that we actually
need research on emergency contraception.” —Federal legislator
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“Ehhmmm … I personally have conducted some research at a stage … collected some data on the
awareness … the knowledge … and attitude on emergency contraception … among adolescents …
Particularly youth corpers, and I am in the process of writing up … but my observation is that not many
people know about emergency contraception.” —Senior executive, medical specialists association
“What are we doing research on EC for? When there are other areas of needs. We want to know …
how many of our health facilities are providing emergency obstetric care and all those things. We don’t
have resources to do that. The last [survey of facilities] … was in 2002, and that’s an obsolete document
… now is 2011—almost nine years!”—Departmental deputy director, FMoH
Policy considerations for EC in Nigeria

Most participants supported the view that EC should, as a provision of the National Family Planning
Policy, be made widely available as part of the contraceptive mix. There was overwhelming enthusiasm
among stakeholders for supporting EC’s availability to the younger population at risk of unprotected
intercourse and its potential consequences. While most interviewees were uncertain of whether national
EC guidelines in Nigeria exist, EC’s availability and widespread distribution were strongly recommended
by all interviewed stakeholders, and undoubtedly positive signal for EC policy in Nigeria.
“Yeah I think it is better (EC) as a part of the (contraceptive) mix, and not singling it out to promote
it, because when you promote it, you are promoting its use at the expense of regular use of contraception
… yeah! … Young people in steady relationships would be able to use regular contraceptives.”
—Head of medical team, Muslim Women’s NGO
“Of course! Our belief is that if you go out there and see what some young women go through because
they don’t really know that there is something they can do immediately in the period post sexual
intercourse. Some of them have gone into … carrying pregnancies they never intended to, and in some
instances it could lead to the termination of those pregnancies, and which also have some injurious impact
to their health, or the health outcome may be detrimental. So I am strongly of the view that it should be
part of the family planning regimen in Nigeria.”—Deputy director, leading health social
marketing institution
“Absolutely! It should be! It should be!!! Anytime, you teach contraception, emergency contraceptives
should be the first because it’s the one that prevents the deaths immediately.”—Federal legislator
“I think it (EC) should be!! [in the national guidelines]. People may argue that the population of those
who may need it may not be that significant, but I think if you really look closely, many young people
coming with unwanted pregnancies, if they have had enough awareness, then you will know that many of
these pregnancies could have been prevented through EC. And such population usually would not take
routine family planning.”—Senior executive, medical union
“EC should be part of the family planning program in Nigeria because the level of development and
information available to users suggests the need for it. Prevention they say is better than cure, since other
preventive methods are not readily available, EC is a quick intervention.”
—Departmental head, health sector regulatory agency
“Providers like it! Based on the high demand for ECs in Nigeria, the patent medicine vendors are
motivated to provide a wider range of services than the public sector, but they will need to be trained on
the use of the product.” —Program manager, bilateral development assistance agency
These examples illustrate EC’s support and consideration within the Nigerian policy circle, from a diverse
range of representatives. Participant responses did not suggest repeated use of EC is encouraged,
however, as most stakeholders were unaware of repeated EC use in Nigeria and were not sure
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if such practices are associated with side effects. They did not particularly support repeated use. In
addition, they did not readily perceive the health and social consequences of EC’s unavailability when
clients require it. Respondents supported, however, regular counseling and referrals of women tending to
repeat use, for other more regular methods of contraception.
“What do you want [women] to do? The women are protecting themselves, repeat use could be dangerous
since they don’t know how to use them properly … but women will use it.”
—Chief technical officer, federal ministry
Another respondent stated:
“Like I said earlier, the class or category of clients that needs EC ‘on a routine basis’ is a peculiar
group. This is a group that is not likely to buy into routine or conventional family planning … ok! And
yet they are sexually active and are naturally prone to pregnancies. These groups of young people, when
they are aware of EC, do use them repeatedly. Is this a problem? Certainly it is in the sense that for
such a group of individuals, it is safer in terms of protecting them from unwanted pregnancies if they
would buy into routine family planning, but if you look at all the methods of routine family planning,
they are not exactly fitted for most of them not just because of the safety and efficacy … no!, but because
of the secrecy associated before going into it. For this reason, they go for repeated EC use. Now, the
unsafe nature of EC is that, the more you use it repeatedly, the chances of its reduced efficacy is higher
and therefore the risk of getting pregnant, that is failure from using it is also higher and the subsequent
consequences of unwanted pregnancy. Beyond these, I don’t see any problem associated with it.”
—Senior executive, medical union
A minority view is represented by those who feel EC should be strictly regulated, supplied only after
prescription, and that repeated use should not be tolerated:
“Yes, they do, and it is a problem. For youth, especially university students, for as many times they have
sex, the drugs are used for fear of pregnancy. The males share the same view. There is need for research
and the results used in the control of the drug. Therefore, usage should be restricted to prescription order
which is filled-in by a registered pharmacy to ensure control along the distribution system. Emergency
contraceptives are hormonal based, hence repeated use will create an imbalance in the system and the
effects are better imagined.”—Department head, federal regulatory agency
“That is where the abuse comes in…. when they just want to be using it instead of going on the regular
pills ,,, and the regular ones are there, people have been trained, we have a lot of people trained and on
all the methods.” —Deputy director, federal ministry

Service delivery, supply, and demand

Respondents unanimously agreed that procurement of EC products in Nigeria is neglected by the
government and is predominantly donor-driven, largely from one source. With Nigeria’s large and
growing population, increasing government participation in procuring EC and other FP commodities is
seen as necessary by most interviewees. Even EC’s marketing in Nigeria has been identified as polarized
and monopolized, leading to poor satisfaction and cooperation among key stakeholders:
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“For as long as we keep the same supply and distribution of what we have, it’s a huge challenge. We
have only one source of public commodity—UNFPA. Only one social franchise—SFH. This is
ridiculous for a country of over 150 million!! I can even understand the UNFPA thing, you understand
because the source is pulled from a lot of places and they go to the manufacturers, but the social franchise
involved in social marketing is only one group. Then, there is a problem because you don’t challenge
them; they do what they want to do, and you buy because you have no choice. I like SFH but I don’t
like monopoly” —Head of medical team, Muslim women’s NGO
This observation is, in part, corroborated by another:
“Well … first and foremost, if you look at problems of supplies within the pipeline … the question is
really there’s no coordinated supply chain system for procurement in the country. Most procurement are
done, not even by the national procurement system, but by individuals who think it is good business. So,
you don’t have any coordinated response and to that extent, we can’t even quantify what we need. So the
issue is that we don’t even know the level of need for EC in the country. Because the procurement system
is not coordinated, and it is not only to EC …virtually in the last two years, we tried to come back to
what we use to do in the ‘80s where there’s a quantification process that leads to forecasting before you
procure family planning contraceptives methods generally … but in the mid ‘90s to 2000 that system
collapsed because it is donor driven. So … if you ask me … we even have a defined pipeline system for
EC in the country? I’m afraid, no!” —Senior executive, national FP organization
All stakeholders interviewed shared the opinion that EC is appropriate for all categories of women who
need it, but more so for young, unmarried women who have irregular and unpredictable intercourse and,
therefore, do not require regular contraceptive methods. There was also consensus that all cadres of
providers should be allowed to provide EC to clients, and that it should be non-prescriptive because of
its emergency nature and the secrecy around its use. Stakeholders believed that restricting EC provision
as a prescription drug, or only for provision by some categories of service providers in selected formal
settings, will defeat the drug’s emergency purpose:
“I believe all cadres of health care providers should provide or be involved in the prescription of EC. All
the service delivery points should be involved in the provision of EC but a monitoring and regulatory
system should be set up to effectively control the use of EC.”
—Program manager, bilateral development assistance agency
Lack of awareness among clients on one hand, and lack of EC availability on the other, have been
identified as the greatest barriers to EC use in Nigeria. Most respondents believe most women in Nigeria
do not know EC exists, let alone know where to obtain it, complicated even further by the fact EC is not
routinely available at convenient locations, or at a cost affordable to all. Some stakeholders opined that
the lack of knowledge about EC among providers and preponderance of counterfeit drugs also
contribute to access-related problems manifested in client dissatisfaction with the commodity. Inability to
provide clients with adequate information on dosage, timing, and related issues such as side effects often
leave clients confused, resulting in lack of use:
“So if you look at it from that perspective, I mean looking at your question, I would think that one big
obstacle is sensitizing women on the availability, how to get it, when to use it and where to get it. Once
we take care of these … the barriers. I think the acceptability level would be high …”
—Senior executive, national FP organization
“Availability, knowledge, accessibility are the common barriers to women accessing the product.”
—Program manager, bilateral development assistance agency
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“One, once you recommend a drug that fails your client will lose confidence in you. The second one, is not
knowing the appropriate regimen to take … what to do in such a situation. Some will say hooo! give a
start dose, then 12 hours later … but for us from experience, all of them work either immediately or 12
hours apart, but the issue is knowing what to do at a particular moment. And some say ‘oooh! after 48
hours all hope is lost’ … all hope is not lost, you can still help that woman in question. So, knowing
what to do at a particular period, the effectiveness, how long it will last before it goes down is also very
key.” —Deputy director, leading health social marketing institution
Recommendations

Various suggestions and recommendations for improving EC in Nigeria were elicited from KOLs. Of
particular importance is the Federal Ministry of Health’ role, whose leadership, especially for FP generally
and EC specifically, has diminished over the years, along with regulation and oversight, however the
federal government is the sole body in Nigeria with required capacity and the infrastructure for catalyzing
widespread EC use of EC:
“I think the key player, of course, is the Federal Ministry of Health, which is the center point of health
policies in this country. But this should also trickle down to state and local government ministries of
health because legislation for health in this country is on the concurrent list.”
—Senior executive, medical union
Another recurring recommendation was the need for massive client and provider education and
sensitizing them to EC’s availability and use. Mass media was identified as key for improving the EC
environment in Nigeria, as the majority of Nigeria’s EC users receive their information from mass media.
“The first is to change behavior towards EC use and that I will do through massive enlightenment using
the mass media. The second, it is to ensure that providers are well trained to the extent that they can
counsel very well on EC provision. And the third, is to ensure that there’s a coordinated pipeline system
for EC in Nigeria.” —Senior executive, national FP organization
Increasing participation of the federal, state and local governments, as well as enhancing provider and
client understanding, are not all that are required for expanding EC access in Nigeria: Collaboration and
participation by local pharmaceutical companies must also be sought. Their collaboration will ensure
large-scale local production at an affordable price:
“And probably enable one of the indigenous pharmaceutical companies to go into production of
something like levenorgesterone.”—Senior executive, medical union
Further suggestions for improving EC services and sustaining quality involved continuous training,
mentoring, and close supervision of service providers. Greater collaboration and networking between
relevant authorities and regulatory bodies was recommended for ensuring strict quality control:
“Improve the knowledge of providers through regular training, mentoring, and supervision.”
—Program manager, bilateral development assistance agency
“Well I think there is need for all sectors involved in this … the manufacturers, the importers to rally
round with regulatory agencies … and then also see how they can put in place a kind of regulation that
could promote the use of EC and widen the access and also remove hindrances through policy measures
… so I think it is a collective effort on the part of the policy makers, the providers, etc.”
—Unit deputy director, regulatory agency
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Programmatic Implications
These research findings have several programmatic implications, both for providers and stakeholders. As
less than half of EC providers in Nigeria have ever received training on EC, and as EC knowledge is
directly related to such training, there is dire need in Nigeria for training providers on EC, especially
those in the private sector. Training should particularly target PMVs and pharmacists who dominate EC
sales (66% of the market combined).
The sale and purchase of EC is legal in Nigeria and is included in the FP and RH service delivery
protocol. This is not enough. The service protocol is only visible seemingly on the bookshelves of the
Federal Ministry of Health and is not widely distributed to, or read by, intended recipients. It is, indeed,
quite striking that only one of 407 providers interviewed understood that EC protects against pregnancy
for as many as 120 hours post-intercourse, while EC is included in the national service delivery protocol.
While EC knowledge and attitudes have improved substantially in recent years, negative perceptions are
still rife among providers in Nigeria. Over 10 percent of surveyed providers still believe EC is an
abortifacient, and the majority is averse to repeated use. Moreover, counseling by providers is not routine
for EC clients. Consequently, FP and EC counseling training, EC brochures and information
distribution, and national service delivery guideline distribution to all facilities must be given greater
attention within FP policies and programs in Nigeria if EC demand and supply is to be significantly
improved.
The Nigerian government needs to assume a leadership role in FP and EC commodity procurement and
distribution, ensuring availability of high quality and effective products at prices young people can afford.
Government officials must be cognizant of the changing realities of young people today. The strong
support for EC expressed by interviewed government officials, backed by requisite action, will ensure EC
is widely available within public sector facilities and that all of their providers are trained and wellinformed.
While escalating EC use through the public sector is important, the private sector’s role must not be
ignored; rather, synergy between the two sectors should be fostered. Since Nigeria’s private sector is
mainly interested in selling EC for profit and provides it to any woman who can buy it, a window of
opportunity exists for EC advocates to work with this sector for improving EC supply and demand with,
most importantly, improved skills for improved, quality service delivery.

Summary and Conclusions
EC is well-known in urban Nigeria, and is controlled by the largely unregulated and unmonitored private
sector, with significant quality and client satisfaction implications. As government continues an
indifferent role, FP and EC procurement and supply is almost entirely though donor agencies. This is not
a sustainable situation. For EC availability and affordability to become standard and established, in both
the private and public sectors, at quality and prices most users can afford, policy action is required, along
with increased education for both clients and providers. Important information about EC that should be
widely disseminated to both clients and providers includes its legality in Nigeria; its non-interference with
established pregnancies; its safety, without adverse effects, for repeated use; its efficacy for as many as
120 hours following unprotected sex; and its suitability for all women, irrespective of age and marital
status.
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